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BRCA1 E3 LIGASE INHIBITORS INDUCES SYNTHETIC 
LETHALITY IN CPT RESISTANT CELLS 
ELIZABETH UNAN 
ABSTRACT 
Camptothecin and its analogues (CPTs) represent one of the most potent classes 
of anticancer drugs used to treat several solid tumors. CPTs bind topoisomerase I during 
the replication process and cause DNA damage that results in cell death. However, its 
effectiveness is limited to 13-30 percent of patients. TopoI cuts and re-ligates DNA 
supercoiling but in the presence of CPT it fails to re-ligate DNA and collision of 
replication forks leads to DNA double strand break (DNA-DSB) and cell death.  
However, in resistant cells, due to deregulated kinase cascade, topoI is continually 
phosphorylated by DNA-PKcs and rapidly degraded by the ubiquitin proteasomal 
pathway (UPP). It has been found that BRCA1 plays a key role in imparting cellular 
resistance to topoI inhibitors. Importantly, BRCA1 ubiquitinates topoI in response to 
CPT. We hypothesize that disruption of BRCA1 binding to phosphorylated topoI would 
interrupt the resistance mechanism resulting in higher cellular sensitivity of CPT. Based 
on an in-silico drug screen, we identified a compound that inhibits topoI degradation by 
blocking BRCA1 binding. Imaging and survival assays findings are consistent with the 
hypothesis that BRCA1 plays a role in CPT resistance through its co-localization with 
topoI, and we speculate this role is through UPP degradation. CPTs are commonly used 
in combination with cytotoxic compounds, but this study focuses on discovering 
compounds that can overcome resistance without causing further cytotoxicity.	  
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INTRODUCTION 
Topoisomerase I 
Topoisomerase I enzymes, essential to DNA replication, work by cutting DNA 
one strand at a time, transiently, and then joining the strand by transesterification [6]. 
During the replication process, topoI continually cuts and re-ligates  supercoiled DNA 
and between cutting and re-ligation reaction a controlled rotation reduces the supercoiling 
[7]. It was discovered in 1985 that this prominent DNA replication enzyme is targeted by 
Camptothecin [2]. Functional topoI is needed for normal cell function; if disrupted, cells 
will need to repair the issue rapidly to avoid cell death due to DNA damage. 
Camptothecin 
Camptothecin  and its analogues (CPTs), such as Irinotecan or Topotecan, are one 
of the most potent anticancer treatments available [1].Camptothecin is a cytotoxic 
alkaloid that comes from the bark of the tree Camptotheca acuminate [2]. CPTs 
specifically  target topoisomerase I (topoI), The mechanisms of inhibition is unique as it 
does not inhibit the enzyme activity, rather inhibits the DNA religation reaction leading 
to formation of a cleavable complex and nicked DNA [3]. The nicked DNA is converted 
to DNA-DSB as the progressing replication fork collides to nicked DNA and thus CPTs 
are  most effective in S-phase cells[4]. For example, Topotecan, structure is similar to 
nucleotides and can stack like base pairs in order to bind the DNA of each strand in the 
double strand break (DSB) [5]. It is important to mention that after cleaving the DNA 
backbone, topoI is covalently linked to the DNA phosphate group. This binding 
mechanism allows Topotecan to not only block the re-ligation but also blocks the free 
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3’overhang of DNA that is usually used for protein binding for DNA repair [1]. Through 
prevention of ligation, CPT causes collision of replication forks leading to DNA-DSBs. 
The Bharti lab has shown that BRCA1 plays important role in CPT induced DNA-DSB.  
BRCA1  
Although very widely researched and studied, the entirety of BRCA1’s role in the 
cell is only partly understood. However, it is known that BRCA1 has various roles as a 
checkpoint/tumor suppressor protein [8]. One of the imperative role as tumor suppressor 
is  in aiding with genomic maintenance [6]. In 2012, David Livingston and Daniel Silver 
found that BRCA1 is involved with genome maintenance through its role in the DNA 
damage response (DDR), particularly removing abnormal structures from the replication 
fork [9]. They also found that the N-terminal RING domain and the C-terminal BRCT 
domain are integral to the BRCA1 protein tumor suppression capability. In terms of 
repair, BRCA1 is involved with both conservative and alternative non-homologous end 
joining (C or A-NHEJ); when phosphorylated at Serine 988 by Chk2, BRCA1 supports 
C-NHEJ and is recruited to damage sites on DNA [10]. When DNA suffers double strand 
breaks, BRCA1 associates with several other proteins to aid in the DSB repair [11]. The 
ability to associate with other proteins is reliant upon its BRCT domain, which acts as a 
phosphoprotein binding motif. The BRCT tandem repeats are crucial for the binding of 
BRCA1 to DNA and for conferring its ability to sense DNA damage [8].  
The discovery that BRCA1 acts as an E3 ligase was the next piece of the puzzle 
regarding BRCA1’s role in genomic maintenance [12]. The N-terminal domain of 
BRCA1 was found to have intrinsic E3 ligase activity, which increases when BRCA1 
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heterodimerizes with its binding partner, BARD1 [13]. The BRCA1/BARD1 heterodimer 
ring domain is heavily conserved, and vital to the function of BRCA1; the importance of 
this heterodimer was found to hinge upon its role as a E3 ligase [14]. The RING domains 
of BRCA1/BARD1 utilize the RING-like tertiary structure to coordinate with E2 
enzymes to allow for their E3 ligase activity with ubiquitin [15].  As an E3 ligase, 
BRCA1 is part of a system of enzymes involved in ubiquitination. There are three classes 
of ubiquitin enzymes, E1, E2 and E3s. The E1 enzyme is called the activating enzyme, 
E2s are ubiquitin transferase enzymes, and E3 enzymes are ubiquitin ligases [16]. The 
number of known enzymes in each class increases from E1 to E2 to E3, implying 
increasing specificity of enzyme class. For example, there are a few E1 (2-3 only) 
enzymes that are used broadly, 20 fold increase in the number of E2 enzymes, and 
hundreds of E3 enzymes [17]. The ubiquitin proteasome pathway (UPP) is an important 
biological pathway that is essential for protein turnover. In the UPP, the 26S proteasome 
degrades marked proteins when it recognizes a chain of 5 ubiquitin molecules that are 
attached to the target protein [17]. As a RING finger E3, BRCA1is a mediator between 
activated ubiquitin and the attachment of ubiquitin to proteins [18].  As an E3 ligase, 
BRCA1 marks CPT bound topoI for degradation in resistant cell lines. Currently 
BRCA1’s role in topoI degradation in non-cancerous cells is unknown. Resistance to 
CPT is due to rapid degradation of topoI in response to CPT treatment, sensitive cells 
have low rates of degradation due to their relative stability of topoI.  
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Mechanism of CPT Resistance 
Camptothecin is used as a treatment for several different types of cancer, however 
only 13-30% of patients are responsive to CPT treatment [1]. Due to these low response 
rates, the resistance mechanism against CPT has been of great interest to researchers. 
There have been three main theories regarding the mechanism: low drug accumulation 
due to MDR (multidrug resistance) transporters, topoI mutations, and ubiquitin-
proteasomal degradation of malfunctioning topoI [19]. The resistance mechanisms of 
topoI mutations or MDR transporters have been shown as unlikely options due to the 
rarity of topoI mutations, and evidence that CPT is not a MDR substrate [20]. Therefore, 
the likely resistance pathway lies with the ubiquitin proteasome pathway (UPP), and 
studies have demonstrated that UPP is responsible for topoI degradation [21]. The rate of 
degradation of topoI by the proteasome pathway has been explored by using CPT 
sensitive and CPT resistant breast cancer cells [22]. This study demonstrated that the CPT 
sensitive cells were faulty in topoI degradation. However, resistant cells were able to 
degrade topoI, conferring resistance after CPT binds and inhibits topoI. When 
investigators treated cells with a proteasome inhibitor (MG132) and treated with CPT, 
there was a significant increase in cell death, implying increased sensitivity to CPT by 
blocking proteasomal degradation [22].  
The Bharti lab has demonstrated that resistance to CPT depends on the rate of   
topoI degradation by UPP. They have determined that CPT-bound topoI causes DNA-
DSB, which signals the Ku70/K80 complex to bind to DNA broken strand and they target 
repair complexes to the site of strand break.  DNA-PKs is recruited by the Ku70/Ku80 
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heterodimer, and phosphorylates topoI at serine10, after which BRCA1/BARD1 
recognize topoI-pS10 and ubiquitinates the protein to tag it for proteasomal degradation 
via UPP  [1]. BRCA1’s rold in topoI degradation may be active in the absence of CPT 
through transcription and replication repair mechanisms, but this would be a subtle effect. 
Through the addition of CPT, this repair role is significantly enhanced due to large 
increases in DNA damage and maximizing the number of S-phase cells. In normal DNA 
damage repair, BRCA1 and DNA-PKcs are active. Therefore, their involvement in CPT 
response after DDR is reasonable. The proposed pathway is summarized below in Figure 
1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	1:	Mechanism	of	topoisomerase	I	degradation.	Adapted	from	the	Bharti	lab,	Figure	1	summarizes	the	mechanism	for	topoI	degradation.	Phosphorylated	DNA-PKcs	phosphorylates	CPT	bound	topoI.	BRCA1	recognizes	phosphorylated	topoI	and	ubiquitinates	the	protein,	beginning	the	proteasomal	degradation	of	topoI.	Once	topoI	is	degraded,	CPT	lacks	a	substrate	and	loses	effectiveness.		 
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The literature supports BRCA1’s role in DNA repair, although the mechanism is 
not fully clear, particularly the role of BRCA1 E3 ligase function in DDR. Reid et al. did 
a comparative study of cells with BRCA1 E3 ligase impaired mutant (BRCA1 I26A),    a 
mutant with a BRCA1 deletion and BRCA1 WT. This study showed E3 ligase mutant 
cells responded to two DNA damaging agents, mitomycin C and X-RT like BRCA1-WT 
cells. . However, in a similar experiment with chicken cells when CPT was used as DNA 
damaging agent, BRCA1 E3 ligase deficient cells were sensitized [14]. This work 
supports the findings in Bharti lab. 
In recent years, work on E3 enzyme inhibitors has shown promise as potential 
therapeutic agents. The large number of E3’s, and therefore their specificity, allow for a 
more precise option of inhibition than that of proteasome inhibitors. Thus far no E3 
inhibitors have been approved as a therapeutic agent. In researching the potential of E3 
inhibitors, three strategies have been employed: direct inhibition of their activity, target 
substrate binding, and third affecting the protein’s expression [23]. This possible mode of 
regulation offers a promising new option for artificial control over protein degradation 
and turnover. The Bharti lab hopes to use inhibition of BRCA1 E3 ligase function as a 
mode of overcoming resistance to CPT.  
As stated earlier, despite being widely used in cancer treatment, CPT is only 
effective in a small portion of the patient population. In clinic, the current method for 
treatment of metastatic colorectal cancer is to utilize multiple cytotoxic agents. 
Combination of these treatments has increased the overall survival (OS) of patients; 
however, the progression free survival (PFS) of these same patients lack improvement 
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(Figure 2). Outcomes of clinical trials in colorectal cancer (Fig. 2), as well as those from 
Onivyde trials in pancreatic cancer, show that the combination of these cytotoxic agents are 
failing to improve the PFS of patients. What is needed most are combination drug options 
to target specific resistance pathways.  In the case of CPT, it is necessary to prevent topoI 
degradation after CPT treatment, so cells can undergo cell death.  
 
 
 
 
 
 
Figure 2. Combination therapy survival rates. Clinical trial results comparing overall 
survival (OS) and progression free survival (PFS) changes with Bevacizumab and 
cetuximab. The trial included combination of fluorouracil, leucovorin and irinotecan 
(FOLFIRI), as well as fluorouracil, leucovorin, and oxaliplatin (FOLFOX), capecitabine 
with oxaliplatin (XELOX), and fluorouracil, leucovorin, oxaliplatin, and irinotecan 
(FOLFOXIRI).  
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referred to as D2) was screened and identified based on physiochemical properties for 
blocking the phosphoserine binding site on BRCA1. Using this compound, my 
experiments focus on determining that D2 prevents BRCA1/BARD1 ubiquitination of 
topoI and stabilizes cellular topoI levels. In addition, my work aims at exploring the 
synergistic effects of D2 with CPT treatment in causing cell death. Visualization of these 
effects is supported through immunofluorescence imaging using GFP-tagged topoI and 
RFP-tagged BRCA1 generated with CRISPR/Cas9 technology. The purpose of this work 
is to help identify non-cytotoxic targeted therapy options that overcome the CPT 
resistance pathway for combination in cancer therapeutics.  
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SPECIFIC AIMS 
 
To determine if interruption of BRCA1’s interaction with phosphorylated and CPT bound 
topoisomerase I allows for increased cell lethality, the aims of this study were: 
1. To determine if D2 has cytotoxic effects on CPT resistant cells.  
2. To observe the stabilization of topoI with combination treatment of D2 and CPT.  
3. To observe the synergistic drug effects of D2 with CPT on cell death.  
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MATERIALS AND METHODS  
 
Generation of EGFP tagged TopoI HCT15 cell line: Genome editing using 
CRISPR/Cas9 technology inserted the EGFP gene after hTOPI. Single guide RNA, 
sgRNA, were created using oligonucleotides that matched the spacer sequence of the 
target site, the final hTOPOI exon’s genomic sequence in HCT15 cells. Gibson assembly 
generated the topoI-EFP fusion protein with a EGFP-P2A-Pac cassette [1]. The Pac 
portion allowed for puromycin resistance. The lipofectamin method with wt S. pyogenes 
Cas9 plasmid was used for HCT15 cell transfection, as detailed in Ando et al. 2017. Post 
transfection, selection of cells was accomplished using puromycin, and then sorted by 
Beckman Coulter. Prior to confirmation of successful incorporation of the cassette, cells 
were kept in 2µg/ml puromycin. To confirm incorporation, the genome sequence of 
interest of amplified using PCR in addition to western blot and immunofluorescence 
characterization [1]. The final cell line of HCT15-htopoI-EGFP-4E7 (hereafter referred to 
as HCT15-4E7) contained GFP fluorescing tag. The insertion of GFP into the topoI gene 
is depicted below in Figure 3.  
 
 
 
 
 
 
Figure 3. CRISPR/Cas9 
GFP-topoI genome editing. 
Schematic representation for 
genome editing to integrate 
topoI with EGFP.  	
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Generation of RFP tagged BRCA1: Genome editing using CRISPR/Cas9 technology 
inserted the RFP gene after exon 24 in the BRCA1 gene into previously transformed 
HCT15-4E7 cells. PCR products of the BRCA1 gene sequence were transformed into E. 
coli, and then sgRNA that targeted the BRCA1 stop codon were used. The fusion cassette 
for the donor plasmid consisted of TagRFP-P2A-Pac. This cassette was transfected into 
HCT15-4E7 cells. The same protocol for cell sorting of HCT15-4E7 cells was used for 
the new HCT15-htopoI-EGFP-BRCA1-RFP-473 (hereafter referred to as HCT15-473) 
using sorting with Beckman Coulter. Prior to confirmation of successful transfection and 
incorporation, cells were allowed to grow in 2µg/ml puromycin media for 7 days. 
Incorporation of the TagRFP-P2A-Pac cassette was confirmed by sequencing of the 
genomic DNA from HCT15-473 cell colonies.  
 
 
 
Figure 4: CRISPR/Cas9 RFP-BRCA1 genome editing. Schematic of genome editing 
for insertion of RFP after the final exon in the BRCA1 gene to develop the HCT15-
htopoI-EGFP-BRCA1-RFP-473 (HCT-15-4E7-473) cell line.  
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Tissue Culture 
Growth and maintenance: HCT15 colon cancer cells acquired from ATCC, and 
modified with GFP and RFP insertions, as described above, to generate the HCT15-4E7-
473 line. These were grown in RPMI media with 10% fetal bovine serum (FBS), 100 
units/mL of streptomycin and penicillin. Cells were grown at 37°C and 5% CO2 in a cell 
culture incubator.  
Drug Treatment: CPT treatment was achieved using the SN38, a metabolite of 
irinotecan. The SN38 was purchased from Tocris Bioscience (Minneapolis, MN). 
Western blot analysis utilized antibodies from Novus Biologicals (Littleton, CO). We 
used a pAB anti-topoisomerase I from Novus, catalog number NBP1-30481. The 
compound CMLD-008929 (D2) was provided by Center for Molecular Discovery, 
Department of Chemistry, Boston University. Proteasome inhibitor MLN9708 was 
obtained in collaboration from Takeda Pharmaceuticals (Cambridge, MA).  
Western Blotting 
Treating cells with SN38 (CPT analogue): Cultured HCT15 cells were removed from 
the incubator 14 hours after plating, to maximize the number of cells in S-phase. Four 
100 mm plates with the treatments of DMSO as control, 2.5µM SN38, 3 days treatment 
with D2 and then without D2 for 24 hours before SN38 treatment, and 2.5µM SN38 + 
4.0µM D2. Each plate was treated with its respective treatment and placed in the 
incubator for 3 hours. After 3 hours, SN38 was removed from the treatment media, with 
D2 remaining constant. Plates were then replaced in the incubator with SN38 free media 
for 20 minutes. The 2.5µM SN38 treatment was made by adding 25µL of 1mM stock 
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solution to 10 mL of media. The 4.0 µM concentration of D2 was made by adding 40µL 
of 1 mM D2 stock solution to 10 mL of media.  
Table 1. Western blot treatment timing.  
Time of treatment 3days 24 hrs 3hrs 20 min 
control DMSO DMSO DMSO DMSO 
D2 + SN38 (D2 
removed 24 hours) 
4.0µM D2 0µM D2 2.5µM SN38 0µM SN38 
D2+SN38 4.0µM D2 
0µM SN38 
0µM D2 
0µM SN38 
4.0µM D2 
2.5µM SN38 
4.0µM D2 
0µM SN38 
SN38 0µM SN38 0µM SN38 2.5µM SN38 0µM SN38 
 
Cell Lysis Buffer Preparation: A lysis buffer was used with 150 mM NaCl, 50 mM Tris 
(pH 8.0) 1% NP40, 1 mM DTT, and 1 tablet of proteasome inhibitor was added. Ratios 
and volumes of the lysis buffer are listed in Table 9 (appendix). 
Preparation of Cell Lysates: Cells were harvested by treating cells with 4mL of trypsin 
and placed back in the incubator for 3 minutes. After 3 minutes, plates were removed, 
and the trypsin and cells were pipetted up and down to wash the plate off for efficient 
collection of cells. The 4 mL of cells and trypsin were taken up and diluted in a 50mL 
tube with 12 mL of cold 1x PBS. All four 50 mL tubes with each of the plates’ contents 
were spun down for 5 minutes at 15000 rpm, at 4ºC. The media was then decanted, and 
pellets were broken up with 500µL of lysis buffer and the contents were moved to 
Eppendorf tubes. Samples remained on ice for 30 minutes and then were spun down at 
12000 RMP for 15 minutes at 4ºC. The supernatant was removed and placed in new 
microtubes, pellets were avoided to prevent DNA contamination.  
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Measuring Cell Lysate Concentration: Each sample lysate’s OD was measured to 
determine the protein concentration in the lysate. Concentrations were measured by 
adding 2.5µL of each respective lysate to 800µL of water and 200µL of Biorad Protein 
assay. Tubes was vortexed, at which point a color change to blue was a visual indicator of 
protein presence. A blank was made using 800µL of water with 200µL of Biorad Protein 
assay and 2.5µL of lysis buffer. Vortexing the blank did not produce a blue color and 
remained brown, indicating a lack of protein. Microtube contents were transferred into 
cuvettes for measurement in the spectrophotometer, which determines the amount of light 
absorption in each sample in comparison to the blank. Light absorption indicated the 
protein concentration, measured at a fixed wavelength of 560nm. Measurement in 
comparison to the blank provided workable OD values. The protein concentration was 
normalized for samples using these OD values.  
Lysate Quantity for Western Blot Calculations: The OD values of the samples were 
compared and the corresponding number of microliters to run was determined using 
Equation 1 below.  
Equation 1: (Lowest OD value of samples/OD value of specific sample) x 10 = ___ µL  
Western Blot Analysis: In topoI experimentation, a 7.5% gel of 1.0mm thickness was 
used. The materials and measurements for a 7.5% gel are listed in Table 10 (appendix). 
While waiting for the resolving gel to set, 1x running buffer was prepared using 100mL 
of 10x running buffer and 900mL of distilled water. At this time, the 1x transfer buffer 
was also prepared, this was made by combining 100mL of 10% methanol, 100mL of 10x 
transfer buffer, and 800mL of distilled water in a 1000mL graduated cylinder. After the 
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resolving gel polimerized, TEMED was added to the stacking gel solution and then 
poured and comb inserted. This polimerized after 10 minutes and the gel was ready to 
load.  
Lysate Buffer Preparation:  Based on sample OD values, amounts to run were adjusted 
to equalize protein concentrations. The buffer was prepared by combining 30µL of 1mM 
DTT with 270µL of Lameli sample buffer. Once lysate buffer and lysate samples were 
combined, the microtubes were boiled for 5 minutes and then placed on ice for 2 minutes 
prior to loading.  
Sample Loading: A standard electrophoresis apparatus was utilized, and the prepared 1x 
running buffer poured between the glass panes. The first lane was loaded with 15µL of 
the protein ladder, and samples with lysate buffer were added to their corresponding 
lanes. Running buffer was poured to cover the lanes, and the gel was run with a BioRad 
power source at about 100V for 2-2.5 hours.  
Membrane Transfer: After protein separation completed, the gel was transferred to a 
PVDF membrane of 0.2µm thickness with a wet transfer (BioRad, Hercules, CA). Two 
containers were used to prepare the membrane, first it was activated in 10% methanol for 
1 minute and then moved to a container with cold 1x transfer buffer for 5 minutes. After 
activation, the membrane was included in a transfer cassette in the order: black cassette 
side, sponge, filter paper, gel, membrane, filter paper, sponge, and clear side of cassette. 
The sandwich was inserted in the transfer equipment and run in the cold room (4ºC) 
overnight at approximately 50mA. 
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Western Blot Blocking: To block topoI blots, membranes were rocked at room 
temperature for 1 hour in 5% milk, made by dissolving 2.5g of nonfat powdered milk in 
50mL of PBS-0.05% T.  
Primary Antibody: For topoI, a 1:2000 antibody solution with 5µL of polyclonal anti-
topoisomerase I in 10µL of PBS-0.05% T was prepared and applied to the membrane for 
2 hours. The membrane was kept at room temperature on a rocker. After this time period 
the membrane was washed with PBS-0.05% T 3 times for 5 minutes each. The PBS-
0.05% T solution is made by combining 1 mL Tween, 200mL 10x PBS, and 1800mL of 
distilled water in a 2L bottle.  
Secondary Antibody: For topoI blots, 4µL of anti-rabbit IgG antibody was added to 
12mL of PBS-0.05% T with 5% milk. Prior to secondary antibody application, the 
membrane was washed with PBS-0.05% T 3 times for 5 minutes each. After washing, the 
secondary antibody solution was applied to the membrane for 1 hour at room temperature 
on a rocker. After 1 hour, the membrane was washed 3 times for 15 minutes each using 
PBS-0.05% T.  
Membrane Development: Western Lighting Plus ECL oxidizing reagent and Western 
Lighting Plus ECL enhanced luminol reagent plus were used to visualize the western 
blots. A 1:1 solution of these reagents, 3mL each, was poured on the membranes and 
rocked for 1 minute at room temperature. The membrane was then placed on a piece of 
saran wrap inside a cassette box and saran wrap was folded up to cover the membrane. 
The film was developed in the dark room. For topoI, the film was exposed for 3 seconds 
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before developing. If background was present the membrane was set to rest for 30 
minutes and then developed again.  
MTT (3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Assay 
Cell Counting: HCT15 cell plates were removed from the incubator and trypsinized. The 
HCT15 cell pellet was resuspended in 5mL of media. From this resuspension, 100µL was 
removed and added to a solution of 800µL of water and 100µL of Trypan Blue. This 
solution was vortexed and about 20µL was inserted under the coverslip on a counting 
slide. Four grids on the counting slide were quantified by cell number and averaged to 
obtain the number of cells in solution. 
MTT Plating and Treatment: Based on the number of cells in the solution, the volume of 
resuspended cells needed to obtain 50,000 cells/well was calculated to be 19.2µL/well. 
This volume was pipetted into the wells of a 96 well plate using a multichannel pipet. 
The plate was placed in the incubator overnight. The next day, the media was removed 
and replaced by media with varying concentrations of SN38 or D2 + SN38. Two lanes 
were controls, and had no treatment, the next 2 lanes were D2 controls and had media 
with a concentration of 2.5µM D2. Two lanes were for varying concentrations of SN38 
treatment alone, each treatment in quadruplicate form. The last two lanes were SN38 
concentrations paired with 2.5µM D2. The following SN38 treatments were utilized: 
0.1µM, 0.25µM, 0.5µM, 1.0µM, 2.5µM, and 5.0µM. In the D2 treated lanes, these same 
concentrations were used but in combination with 2.5µM of D2. After removing the 
media and replacing it with its respective treatment media, the plate was positioned in the 
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incubator again overnight. The next day the drugs were removed and each well received 
100µL of drug free media. 
MTT Plate Reading: After drug removal and media replacement, the plate was left in the 
incubator for 2 additional days before adding 10µL of Alamar Blue directly to each well. 
Alamar blue assess the health of cells. This reagent enters cells and is reduced by living 
cells, producing red fluorescence. The fluorescence amount is proportional to the number 
of cells metabolically capable of reducing Alamar Blue, and therefore the amount of 
living cells. The plate was placed back in the incubator and cell death was read after 2 
hours, and results are depicted in Figure 10.  
Clonogenic Assay 
Clonogenic Plating and Treatment: For clonogenic plating, sterile 6-well plates were 
utilized. Each well was plated with 50 cells/well and 3mL of media. The plates were 
replaced in the incubator overnight. After 24 hours in the 37ºC incubator, the plates were 
removed, and triplicates were treated as either control, D2 control, SN38 alone, or 
D2+SN38. Treated plates were then placed back in the incubator overnight. The next day 
the drugs were removed by replacing treated media with 3mL of untreated media. Plates 
were then left in the incubator for 14 days before reading them. Treatments and average 
colony counts are listed in Table 12 (appendix). 
Clonogenic Colony Quantification: Plates were removed from the incubator and the 
media was removed. Colonies were washed with 1x PBS two times and were covered in 
5% crystal violet stain for 20 minutes. After 20 minutes, the stain was discarded, and 
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residual dye was washed off with distilled water. Colonies were counted by hand and the 
survival fraction based on control cells was calculated.  
Sub G1 Assay 
SubG1 Assay Plating and Treatment: Based on the cell count, 100,000 cells were plated 
in each well of sterile 6-well plates. Each well received 3 mL of media and the plates 
were placed in the incubator overnight. After incubating overnight, the plates were 
removed, and the media was aspirated. Each well received 3 mL of media with its 
respective treatment, with concentrations of SN38 varying and D2 concentration 
remaining at 4 µM. The treatment type for each well is listed in Table 13 (appendix). 
Plates were incubated with treatments overnight, after which the drugs were removed the 
next day and replaced with fresh media. After removing the drugs, the plates are placed 
back in the incubator for 72 hours.  
SubG1 quantification: After incubation, the media from each well was removed and 
placed in a labeled 15 mL tube and each well underwent trypsinization. The mixture was 
dispensed into its respective 15 mL tube with its media and 10 mL of cold 1x PBS and 
spun down. The media and PBS are poured out and the tubes were inverted to drain 
liquid from the pellets. For fixation of the cells, 1mL of cold 70% EtOH was dripped into 
the cell pellet while vortexing. After vortexing the pellet and EtOH, the contents of each 
tube were pipetted up and down to mix thoroughly. The tubes were then chilled at -20° C 
overnight or at least 1 hour before preparing them for cell cycle analysis. Once the cells 
were fixed in EtOH and chilled, they were spun down, after which the supernatant was 
discarded. A 1x PBS solution with 2.5 µL/mL Propidium Iodide and 2.5 µL/mL RNase 
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was mixed and 500µL of this solution was added dropwise to each pellet while vortexing. 
If the pellet was not sufficiently resuspended, then the solution was pipetted up and down 
until resuspension was achieved. These tubes were covered with aluminum foil and 
incubated at 37°C for 30 min. After incubation, the tubes were held at 4°C until the cell 
cycle analysis was completed.  
Immunofluorescence Imaging 
Leica fixed cell imaging: HCT15-473 cells were grown on a sterile coverslip for 14 
hours. Cells were treated with DMSO, 2.5µM SN38, or the combination of 4.0µM D2 + 
2.5µM SN38. Control DMSO coverslips were removed prior to treatment. The cells were 
treated for 90 minutes and 3 hours, and at each time mark the respective coverslip was 
removed from the culture media treatment group and washed with 1x PBS. After 
washing, cells were fixed with 3.7% formaldehyde for 25 minutes before permeabilizing 
with PBS-0.2% T (50mL of 1x PBS with 100 µL Triton-X) for 10 min. Coverslips were 
then washed two times with PBS-0.01% T for 3 minutes each. Cellular nuclei were DAPI 
stained at a concentration of 1:1000 diluted into 1x PBS. Imaging was performed on 
Leica SP5 microscope using LAS software.  
96-well GFP cellular imaging: HCT15-473 cells were grown at a concentration of 5,000 
cells/well in a 96-well place for two days. Cells were grown with 100 µL of media. Each 
treatment type was replicated in triplicates and were the following: Control (80 µL 
DMSO), 2.5 µM SN38, 2.5 µM D2, 5.0 µM D2, 10 µM D2, 2.5µM SN38 + 2.5 µM D2, 
2.5 µM SN38 + 5.0 µM D2, and 2.5 µM SN38 + 10 µM D2. Wells designated for D2 
treatment were treated with their respective D2 concentration after the cells had grown 
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for two days. After growing for two additional days in the presence of D2, each well was 
treated with its designated treatment type, with D2 treatment wells having media replaced 
with D2 and SN38 treatments in the media. After 90 minutes of treatment, the GFP 
signal, of each well was visualized on a Nikon deconvolution wide-field epifluorescence 
microscope. The plate was placed back in the incubator for another 90 minutes and 
visualized again at the 3-hour mark.	This experiment was repeated using 7.5 µM D2 
instead of 10 µM D2. 
Live	Time	Lapse	Imaging	
Cell	treatment	and	imaging:	After	counting,	200,000	cells	were	plated	on	two	60	mm	plates	that	had	coverslips	attached	to	the	bottom	of	the	plate.	For	live	imaging	the	Zeiss	LSM	700	microscope	was	used,	and	treatment	was	added	once	the	plate	was	affixed	to	the	microscope.	Each	plate	was	imaged	separately.	After	14	hours	in	the	incubator,	plates	were	affixed	and	readings	of	GFP-topoI	were	normalized	before	the	first	image	with	no	treatment.	After	acquiring	a	baseline	image	without	treatment,	1.5	mL	of	treatment	media	was	added	to	the	1.5	mL	of	existing	media	in	the	plate.	Volumes	were	adjusted	for	to	achieve	2.5µM	SN38	treatment	or	2.5µM	SN38	+	4.0µM	D2	treatment.	Images	were	taken	every	5	minutes	for	45	minutes	through	automated	ZEN	software.	Only	one	plate	was	accommodated	at	a	time	and	both	treatment	types	utilized	the	same	settings	and	adjustments	on	the	microscope.	Each	plate	had	three	locations	chosen	and	imaged,	with	each	location	taking	snapshots	of	the	GFP	signal	every	5	minutes.	Still	images	from	the	live	time	lapse	videos	were	extracted	using	ImageJ	software.	 	
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RESULTS 
 
TopoI stabilization experiments: 
Western Blot: 
Cells from the CPT resistant colon cancer cell line HCT15 were treated with 
SN38, SN38 with D2 the BRCA1 blocking compound, or D2 alone. We hypothesized 
that cells treated with SN-38 and D2 would prevent significant topoI degradation due to 
the lack of BRCA1 ubiquitination. This would result in stabilization of the topoI protein. 
We expected that D2 would have reversible effects, which was confirmed by seeing the 
degradation of topo I in lane 3 of Figure 5. The compound D2 was hypothesized to 
stabilize topoI through blocking the binding of BRCA1/BARD1 to phosphorylated topoI. 
Figure 5 shows that the topoI signal was significantly diminished indicating degradation 
with treatment of SN38. In comparison, the levels of topoI increased with combination 
treatments of D2 + SN38, as compared to SN38 alone. The lighter band seen in lane 3 
demonstrates that the effect D2 has on preventing degradation may be reversed despite 
long treatment times. This was seen in lane 3 where SN38 effectively degraded topoI 24 
hours post termination of D2 treatment. We noted that SN38 treatment (lane 2) results in 
topoI degrading considerably in comparison to the control (lane 1). Therefore, the strong 
band in lane 4 also shows that D2 exhibits topoI stabilization but can be easily reversed 
when treatment is removed for 24 hours, as seen in lane 3. The data indicates that D2 is 
effective in stabilizing topoI with continual treatment through the reappearance of a band 
in lane 4.  
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TopoI- EGFP signal stabilization: 
 HCT15-473 cells were treated with a 2.5 µL/mL SN38 unless mentioned 
otherwise and varying concentrations of D2 to determine the drug efficacy. It was 
observed that the GFP signal degrades significantly in these cells after SN38, treatment 
both at the 90 minutes and 3-hours. Furthermore, we hypothesized that the combination 
treatments of SN38 and D2 would stabilize the topoI-GFP signal at both reading times, 
indicating that topoI degradation was reduced. We hypothesized that stabilization would 
be represented by both overall fluorescence as well as maintenance of nucleolar topoI-
GFP signals. The SN38 treatment acts strongest on S-phase cells, so while many cells do 
have very faded GFP signals, those that were undergoing S-phase saw the most 
stabilization of the signal. In the early experiments, we used 2.5µM, 5.0µM, and 10µM 
D2 concentrations, however cell death was observed in the 10µM sample (Figure 6). As a 
result of this cell death, in the second set of experiments we used 2.5µM, 5.0µM, and 
replaced the 10µM with 7.5µM of D2. The results indicate that the optimal stabilization 
of the topoI-GFP signal is observed when D2 concentration was 5µM and 7.5µM and 
Figure 5. TopoI stabilization 
in D2 and SN38 treated cells: 
HCT15 cells were treated either 
with DMSO as control (lane 1), 
with SN38 (lane 2), 3 days 
treatment with D2 and removed 
for 24 hours then treated with 
SN38 (lane 3), and with D2 and 
SN38 (lane 4). Cell lysates were 
analyzed using immunoblotting 
with anti-topoI.   
					1														2															3																		4	
IB:	An+-topoI	
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SN38 2.5µM (Figure 7).  In both Figure 6 and Figure 7 it can be seen that panel E, 
representing SN38 treated HCT15-473 cells, has a highly reduced topoI-GFP signal. 
When comparing panel E and the combination treatment D2 + SN38 panels of F, G, and 
H, it can be seen that the topo-GFP signal is stronger in the combination treatment panels. 
In Figure 7 the control wells with no treatment, 2.5µM D2 control, 5.0µM D2 control, 
and 7.5µM D2 control, all have similar levels of topoI-GFP signal. This indicates that 
there is no effect of D2 on topoI-GFP levels in the absence of SN38 .  
 When formulating the concentration of D2 treatments, it was important that both 
response and lack of cytotoxicity were taken into account. Therefore, each combination 
D2 and SN38 treatment type was accompanied by a control for the respective D2 
concentration. We observed that the 10µM D2 concentration resulted in moderate cell 
death (Figure 6, panel D), therefore we changed our highest D2 treatment to 7.5µM 
(Figure 7, panel D). We found that cell survival was good in the D2 controls. After D2 
treatment cell structure and nuclear structure appear to be normal. This was confirmed 
using clonogenic and subG1 assays.  
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Figure 6. GFP-topoI stabilization. Images of GFP tagged HCT15 cells. Image (A) has 
no treatment, control.  (B) D2  2.5uM (C) D2 treatment, 5.0 uM (D)  10.0 uM D2. Image 
(E) is treated with 2.5 uM SN38. Images F-H are cells treated with 2.5 uM D2 + 2.5uM 
SN38, 5.0 uM D2+2.5 uM SN38, and 10.0 uM D2+2.5 uM SN38, respectively. All cells 
were treated for 3 hours. Imaged on a Nikon deconvolution wide-field epifluorescence 
microscope (X40).  
 
 
Figure 7. GFP-topoI stabilization modified. Images of GFP tagged HCT15 cells. Image 
(A) has no treatment, control.  D2 controls consist of Image (B) with 2.5uM D2 
treatment, image (C) with 5.0 uM D2, image (D) with 7.5 uM D2. Image (E) is treated 
with 2.5 uM SN38. Images F-H are cells treated with 2.5 uM D2 + 2.5uM SN38, 5.0 uM 
D2+2.5 uM SN38, and 7.5 uM D2+2.5 uM SN38, respectively. All cells were treated for 
3 hours. Imaged on a Nikon deconvolution wide-field epifluorescence microscope (X20). 
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Immunofluorescence fixed cell imaging: 
 
96-well degradation imaging gave us a visual comparison of cell survival and 
topoI degradation when comparing SN38 treatment to combination treatment with D2. 
Fixed cell imaging on a confocal microscope allowed us to get a closer view on the effect 
of SN38 or combination treatment on topoI GFP signal on a single cell level. This 
technique also allowed us to visualize the nuclear relocalization of topoI from the 
nucleolus to the nuclear plasma. To determine whether topoI degradation is reduced, and 
therefore the protein is stabilized within the nucleus, HCT15-473 cells were grown on 
sterile coverslips and visualized on the confocal Leica SP5 microscope. It is known that 
topoI localizes in the nucleolus. Cells were visualized with DAPI staining and the 
GFP/RFP tagged signals.  As a control, HCT15-473 cells were grown overnight on 
coverslips and then fixed and stained with DAPI the next morning. We hypothesized that 
the cells treated with SN38 and D2 combined would have higher levels of GFP 
fluorescence in both the 90 minute and 3 hours treatment times than the SN38 alone 
treated cells. We expected that the inhibitory compound D2 would prevent overall and 
nucleolar signal decrease which indicates topo1 degradation. The DAPI stain was 
expected to be consistent across all cell treatment types. Figure 8 shows a comparison of 
individual GFP signals from each treatment type, as well as the overlaid image with 
DAPI and RFP signal. Both the 90 minutes and 3-hour D2 + SN38 treatment groups 
show higher levels of GFP, specifically in the nucleolus. We quantified these differences 
using the ImageJ software package and show higher levels of GFP fluorescence in 
combination groups in Figure 9 below. Quantification was normalized by utilizing 3 cells 
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per group. Figure 8 shows that overall cell GFP-topoI signals were sustained in 
combination treatment, but also the nucleolar signal was preserved. TopoI re-localization 
with SN-38 treatment is a rapid process. Within 10 minutes of CPT treatment, topoI 
leaves the nucleolus and enters the nuclear plasma, UPP mediated degradation follows.  
 
 
Figure 8. HCT15-473 immunofluorescent imaging of topoI GFP: Cells were grown 
on sterile coverslips and treated with SN38 for either 90 minutes or 3 hours. Panels A, C, 
E, G, and I show the GFP signal of CRISPR/Cas9 GFP tagged topoI protein in control 
cells (A), 90 minutes SN38 treatment (C), 90 minutes D2+SN38 treatment (E), 3 hours 
SN38 treatment (G), and 3 hours D2+SN38 treatment (I). The lower panels show overlaid 
images of the corresponding upper panel, cellular nuclei were stained with DAPI. Cells 
were imaged on the Leica SP5 confocal microscope (X60 oil).  
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In order to evaluate the effect of CPT treatment on BRCA1 expression and 
localization, fixed cell immunofluorescence was used. Imaging of HCT15-473 cells 
revealed that upon CPT treatment, and combination D2 with SN38, the RFP signal 
increased and was clearly visualized. The signal appeared to be stronger, as well as more 
evident, given the degradation effect of SN38 on topoI, reducing the GFP masking effect. 
Control cells showed very low RFP signal and high GFP signal. However, upon 
treatment of HCT15-473 cells with 3 hours of SN38 the previously strong signal of topoI-
GFP is lessened, revealing a stronger BRCA1-RFP signal (Figure 10). HCT15-473 cells 
that received 3 hours of the combination SN38 with D2 showed GFP stabilization and 
increased RFP signal and nucleolar stabilization of topoI (Figure 10). Both the SN38 
treatment alone, as well as the combination therapy, showed higher RFP signal which 
revealed BRCA1 localization in the nucleolus. We observed that the RFP signal was 
present both in the nuclear plasma as well as the nucleolus.  
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Figure	9.	Comparison	of	
GFP	fluorescence.	GFP	fluorescence	quantification	of	HCT15-473	cells	seen	in	Figure	8.	GFP	signal	was	quantified	using	the	analyze	function	in	the	software	package	ImageJ.		
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Figure 10. Stabilization and co-localization of topoI-BRCA1 in response to D2: Cells 
were grown on coverslips and after fixation were stained with DAPI and visualized using 
Leica SP5 confocal microscope. Control cells showed topoI-GFP in the nucleolus (A). 
Cells were treated with SN38 for 45 min (B) and 90 min (C). Cells treated with D2 for 72 
hours were treated with SN38 for 3 h (D).  Cells treated with SN38 for 3h (E). Control 
cells RFP signal (F). RFP signal of 45 min SN38 treated cells (G). RFP signal of 90 min 
SN38 treated cells (H). RFP signal of Red indicates localization of BRCA1-RFP (X60). 
 
Fixed cell imaging allowed for us to visualize an increased RFP signal upon 
treatment. After this observation we evaluated possible co-localization of topoI and 
BRCA1 using their GFP and RFP signals, respectively. HCT15-473 cells with 
combination treatment for 3 hours demonstrated strong RFP signal, as well as BRCA1 
localization within the nucleolus. When the signals were overlaid, we observed co-
localization of GFP and RFP in the nucleolus, indicated by the yellow tone of nucleolar 
areas (Figure 11). 
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Time Lapse Live Cell Imaging: 
Imaging of GFP signal degradation or stabilization in live cells was used to 
investigate the timeline of topoI degradation in SN38 treated cells. This also offered 
visual confirmation of topoI-GFP stabilization by D2. Two plates were used, one with 
SN38 treatment alone, and another with the combination treatment of D2 + SN38. Each 
experiment begun by imaging the plate’s GFP reading prior to treatment, a 
pretreatment/control image. Results show that the SN38 alone treatment group had clear 
loss of GFP signal over the time of the experiment. While the D2 + SN38 group showed 
some GFP loss, although minimal, a stronger signal was still preserved. By pulling out 
several stills from the pretreatment, 5 minutes of treatment, 25 minutes of treatment, and 
40 minutes of treatment, we observed that combination treatment was effective in 
preventing significant loss of GFP-topoI. We noted that signal was maintained in overall 
intensity as well as in the nucleolus. The GFP signal in SN38 alone cells was degraded 
over time and had diffused out of the nucleolus into the nuclear plasma (Figure 12). 
Figure 11. TopoI and BRCA co-localization. HCT15-473 cells were grown on 
sterile coverslips and treated for 3 hours with 2.5µM SN38 + 4.0µM D2. Panel A 
shows the topoI-GFP signal and panel B shows the BRCA1-RFP signal. Cells were 
treated with DAPI (C). Panel D shows the overlaid image of these signals. Cells 
were imaged on Leica SP5 confocal microscope (X40).  
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Figure 12. HCT15-473 cells with SN38 and D2 + SN38 treatment: Cells were plated 
on sterile 60 mm plates with attached coverslip at a concentration of 200, 000 cells/plate. 
Cells were imaged for 40 min as a live time lapse on the Zeiss LSM 700 microscope 
(X60). Panels A and E are images of cells before treatment. Panels B-D are images of 
cells treated with SN38 for 5, 25 and 40 minutes of treatment, respectively. The panels F-
H are D2+ SN38 treated cells for 5, 25 and 40 minutes of treatment. Green fluorescence 
is the result of GFP fluorescence, and cells were treated with 2.5uM SN38 and/or 4.0uM 
D2.  			
D2 enhances the cellular sensitivity of SN38: 
MTT Assay 
A MTT assay was conducted in order to determine the synergistic effect of D2 
with SN38 treatment on cell death. We hypothesized that by preventing BRCA1 from 
ubiquitinating topoI, D2 would allow CPT bound topoI to remain inactive long enough 
for cell death to occur. In the normal resistance pathway, when CPT binds topoI, the cell 
attempts to quickly remove and destroy the DNA-linked topoI so that the cancer cell can 
repair and continue its replication and division. However, we hypothesized that the lag in 
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UPP destruction of CPT-bound topoI through D2-mediated inhibition of BRCA1 binding 
to TopoI, would allow for a synergistic effect of CPT and D2 treatment for higher levels 
of cell death than CPT treatment alone. In the D2 control group the cell survival was 
similar only slightly lower than that of the control group, indicating very low cytotoxic 
effects of the compound alone (Figure 13). The HCT15 cells were treated with a 
consistent 2.5µM concentration of D2 and varying concentrations of SN38. We observed 
that the combination treatment of SN38 and D2 resulted in higher amounts of cell death; 
however, the difference between SN38 alone and the combination was not as large as we 
anticipated. In future experiments, we would use a higher concentration of D2, given that 
later work indicated that a 4.0µM concentration is more effective.  	
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Figure	13.	MTT	Assay	
of	HCT15	treated	
cells.	CPT	resistant	HCT15	cells	were	plated	using	a	sterile	96-well	Falcon	plated	with	50,000	cells/well.	After	72	hours	of	treatment	cell	number	was	quantified	on	Tecan.	Dashed	line	indicates	control	reference	cells.	D2	control	wells	had	85%	surivival	vs.	control	Cell	death	was	compared	between	SN38	and	SN38	+	D2	treatment.		
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Clonogenic Assay 
 A clonogenic assay was conducted to test the synergistic effects of SN38 with D2 
for cell death in HCT15 CPT resistant cells. After observing the less than optimal effects 
of 2.5µM D2, these cells were treated with 4.0µM D2. The survival of HCT15 cells 
exposed to varying concentrations of SN38 was compared those exposed to 4.0µM D2 in 
combination with the varying SN38 concentrations. Table 1 shows the cell colony count 
of the SN38 alone treated cells, as well as control DMSO (0nM group) treated cells. 
Table 4 shows the cell colony count for the SN38 and D2 combination treatment, as well 
as the D2 control cells (0nM group). Each of these groups’ counts were converted to PE, 
percentage of the control HCT15 cells (table 2) and from that the survival fraction was 
calculated by the following equation: 
 
Survival Fraction: Colony number/(50 *Average PE/100) 
 
Table 2. Cell count of control cells and cells exposed to SN38 concentrations 
SN38 concentration Cells Well 1 Cells Well 2 Cells Well 3 
0 nM 22 18 19 
0.5 nM 23 16 18 
1.0 nM 21 23 18 
2.0 nM 19 16 16 
3.0 nM 16 18 15 
4.0 nM 14 20 14 
5.0 nM 17 15 13 
6.0 nM 16 13 16 
10.0 nM 12 10 12 
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Table 3. Percentage of control cells surviving post exposure to SN38 
0 nM SN38 concentration  Percentage of Cells (PE) [colony 
#/50*100] 
Well 1 à (22/50)*100 44 
Well 2 à (18/50)*100 36 
Well 3 à (19/50)*100 38 
PE average 37.333 
50*PE Average/100 186.67 
 
To find the survival fraction for cells exposed to SN38, the number of surviving cells was 
divided by the 50* PE average (37.333) or colony number/186.67. 
Example: Well 1 of 0nM treatment:  22/186.67 = 1.178569 
Table 4. Survival Fraction (SF) of HCT15 cells exposed to SN38 concentrations 
SN38 
concentration 
Well 1 SF Well 2 SF Well 3 SF SF Average 
0 nM 1.178569 .964284 1.017855 1.053569 
0.5 nM 1.232141 .857141 .964284 1.07855 
1 nM 1.124998 1.232141 .964284 1.107141 
2 nM 1.017855 .857141 .857141 .910712 
3 nM .857141 .964284 .80357 .874998 
4 nM .749999 1.071427 .749999 .857142 
5 nM .910713 .80357 .696427 .80357 
6 nM .857141 .696427 .857141 .80357 
10.0 nM .642856 .535713 .642856 .607142 
 
The same values were calculated for HCT15 cells that were treated with the combination 
therapy of D2 (4µM) and varying SN38 concentrations.  
Table 5. Cell colony count of cells treated with D2 and varying SN38 concentrations 
D2 + SN38 
concentration 
Cells Well 1 Cells Well 2 Cells Well 3 
D2 + 0 nM 18 17 19 
D2 + 0.5 nM 10 10 9 
D2 + 1.0 nM 9 9 12 
D2 + 2.0 nM 7 9 9 
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D2 + 3.0 nM 8 9 6 
D2 + 4.0 nM 7 5 8 
D2 + 5.0 nM 6 6 9 
D2 + 6.0 nM 3 10 6 
D2 + 10.0 nM 2 3 5 
 
Table 6. Percentage of surviving D2 control cells post SN38 exposure 
 
4.0 µM + 0 nM SN38 Percentage of Cells (PE) [colony 
#/50*100] 
Well 1 à (18/50)*100 36 
Well 2 à (17/50)*100 34 
Well 3 à (19/50)*100 38 
PE Average 36 
50*PE Average/100 180 
 
Table 7. Survival Fraction (SF) of HCT15 cells treated with 4.0 µM D2 and varying 
concentrations of SN38. 
 
D2 + SN38 
concentration 
Well 1 SF Well 2 SF Well 3 SF SF Average 
D2 + 0 nM .964284 .910713 1.017855 .96424 
D2 + 0.5 nM .535713 .535713 .482142 .517856 
D2 + 1.0 nM .482142 .482142 .642856 .535713 
D2 + 2.0 nM .374999 .482142 .482142 .446428 
D2 + 3.0 nM .428571 .482142 .321428 .410714 
D2 + 4.0 nM .374999 .267857 .428571 .357142 
D2 + 5.0 nM .321428 .321428 .482142 .374999 
D2 + 6.0 nM .160714 .535713 .321428 .339285 
D2 + 10.0 nM .107143 .160714 .267857 .178571 
 
 In order to compare the effects of the combination treatment, the survival 
fractions of SN38 and D2+SN38 treated cells were evaluated. It was determined that the 
survival fraction decreased with combination treatment in comparison to the sole 
treatment of SN38. Comparison of the average survival fractions of each treatment type 
can be seen in table 7 below.  
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Table 8. Average SF value comparison between treatment of HCT15 cells with SN38 
alone or D2+SN38 treatment 
 
SN38 concentration SN38 alone average SF SN38+D2 average SF 
0 nM 1.053569 .964284 
0.5 nM 1.07855 .517856 
1.0 nM 1.107141 .535713 
2.0 nM .910712 .446428 
3.0 nM .874998 .410714 
4.0 nM .857142 .357142 
5.0 nM .80357 .374999 
6.0 nM .80357 .339285 
10.0 nM .607142 .178571 
 
Table 9. Standard deviation of survival fractions between SN38 alone treatment and 
combination treatment of D2 + SN38 
 
SN38 Concentration SN38 treatment  D2 + SN38 treatment 
0 nM .112 .054 
0.5 nM .193 .031 
1.0 nM .135 .093 
2.0 nM .093 .062 
3.0 nM .082 .082 
4.0 nM .186 .082 
5.0 nM .107 .093 
6.0 nM .093 .188 
10.0 nM .062 .082 
 
Figure 14 represents graphical visualization of the survival data presented above. 
This graph shows that there is a difference between the survival fractions of D2 + SN38 
combination treatment groups in comparison to the sole treatment of SN38. The data 
suggests that D2 acts in a synergistic manner, potentially by preventing cells from 
avoiding cell death by blockade of the BRCA1/BARD1 ubiquitination of topoI. The 
yellow line (D2 + SN38) shows drastically greater cell death and smaller survival 
fractions for every SN38 concentration (gray line). This result was in support of our 
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hypothesis that D2 treatment would allow for minimal cytotoxic effects (orange line) 
while allowing for increased cell death when used in combination with camptothecin.  
 
Figure 14. Clonogenic assay survival fraction comparison of HCT15 cells treated 
with SN38 or 4.0µM D2 + SN38. Resistant HCT15 cells were grown for approximately 
15 days after 24 hours of drug treatment. Cell colony survival was calculated using 5% 
crystal violet staining. Cells were treated either with SN38 alone (green), no treatment 
comparison (blue dash), or SN38 and D2 (purple). D2 control cells had 96% survival 
compared to control cells (blue dash).Cells were treated with 4.0µM D2 and varying 
concentrations of SN38, as listed on the x-axis. 
 
SubG1 Assay 
 The SubG1 assay was used to quantify the percentage of cells undergoing cell 
death in response to SN38 treatment and D2 treatment. Treatment groups with SN38 and 
D2 were skewed and abnormal due to overgrowth of the plates. However, control cells 
and D2 control cells demonstrated the lack of cytotoxic effects by D2 (Figure 15). 
Control cells (panel A) demonstrated normal cell cycle proportions, with 3.7% of cells in 
the subG1 phase. In comparison, the D2 control group treated with 4.0µM D2 showed 
similar results with 4.3% of cells in the subG1 phase.  
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Figure 15. Comparison of SubG1 Graphs. Cells were grown in sterile 6-well dishes 
with 150,000 cells/well. Panel A represents SubG1 assay of control DMSO treated 
HCT15 cells. Panel B represents SubG1 assay of D2 treated HCT15 cells, treated with 
D2 for 3 days with 4.0µM D2. SubG1 peaks constituted 3.7% of cells and 4.3% of 
control and D2 control cells, respectively.  
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DISCUSSION 
The Bharti lab has demonstrated in previous work that the CPT resistance 
pathway is related to rapid degradation of topoI [1]. If topoI is stabilized long enough 
then this leads to DNA-DSB and cell death, while rapid degradation helps to repair DNA 
and the cell survives. Our hypothesis that D2 would prevent this degradation when 
treated in combination was confirmed in each of the D2 concentration combinations 
(Figure 7). In all three of these combination treatments the GFP signal was maintained 
and cells no cytotoxic effect was visualized.   
Stabilization was visualized using higher magnification with the confocal 
microscope (Figure 8). These HCT15-473 cells demonstrated that the topoI signal was 
stabilized with combination treatment, but topoI was also stabilized within the nucleolus. 
In SN38 treated cells we observed a rapid re-localization of topoI from the nucleolus to 
the nuclear plasma. When we treated with D2 however, the topoI GFP signal was 
maintained within the nucleolus, even after 3 hours (Figure 8). Fixed cell imaging offered 
important information on overall changes in topoI degradation and stabilization after 
treatment. However, we utilized live cell imaging to get a clearer picture of the timeline 
of SN38 effects on topoisomerase I, as well as how D2 affects the expected results from 
SN38 treatment. We hypothesized there would be quick reductions in GFP signal when 
evaluating the images from SN38 alone treatment and continued reductions with time, 
and when comparing the two treatment groups we would see similar levels of GFP from 
the start to the end in the D2 + SN38 combination treatment. Results confirmed our 
hypothesis, with the exception that GFP signal reduction was not as quick as we 
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anticipated. However, we noted that topoisomerase I was leaving the nucleolus within 10 
minutes of SN38 treatment, and reduction of the evacuated topoisomerase I followed 
progressively with time. In comparison, we found that combination treatment lacked 
significant topoI evacuation from the nucleolus, and the signal was stable over the course 
of imaging. This technique was helpful in seeing the changes in topoI location after CPT 
treatment, and relative topoI levels in the nucleolus and nuclear plasma over time. In 
upcoming experiments, the live imaging will be extended for a longer time period.  
Fixed cell imaging also gave us insight on the localization of BRCA1 in CPT 
treatment through RFP visualization. Imaging of control cells demonstrated that the 
insertion of RFP into the BRCA1 gene was successful, however, the signal was low in 
untreated cells. In treatment cell groups we observed much higher levels of RFP signal, 
and localization of BRCA1 within the nucleolus. Control cells lacked this higher 
expression, and it appears that treatment with CPT or combination of D2 with CPT 
causes this higher expression. Many genes are induced after DNA damage, this increase 
in expression may be due to this inducible response. Further work is needed to identify if 
and how this higher expression comes about. The yellow tone of the signal within the 
nucleolus indicated topoI and BRCA1 co-localization. These results confirm successful 
incorporation of RFP into the BRCA1 gene, as well as demonstrate the potential of future 
experiments involving BRCA1 movement and localization post CPT treatment.  
 Beyond that of imaging, western blot data also supported our hypothesis. The data 
seen in Figure 5 supports the D2 stabilization hypothesis. The reversibility of D2 
demonstrated in lane 3 is ideal for D2 as an alternative option in combination therapies. 
	41 
Lack of effects after 24 hours of D2 removal gives a safer, less toxic, option to 
accompany the cytotoxic agent, CPT. A common option in preventing proteasomal 
degradation are proteasome inhibitors. Although these are very effective, they are 
relatively non-specific. However, D2 offers a specific inhibitor of the UPP pathway for 
CPT treatment. Low response rates in patients and a lack of improvement in PFS (Figure 
2) call for combination treatments, such as D2 + SN38, in which one compound directly 
addresses the resistance pathway of the cytotoxic agent, increasing sensitivity to that 
treatment. One of the critical aspects of this study was to detect the synergistic 
relationship of D2 and CPT.  
 Our sensitivity experiments were designed to determine the ability of D2 to 
increase the sensitivity of resistant cells to CPT treatment. Our synergistic assays focused 
on shorter and longer duration time spans. The data from the MTT assay show supportive 
results, with higher levels of cell death in the D2 combination treatment group (Figure 
13). However, the difference between SN38 alone and the combination treatment was 
minimal.  
 The longer time frame of a clonogenic assay provided a more precise look into 
survival differences between treatment groups. In each SN38 treatment category, the D2 
combination wells had greater cell death. Combination treatments were highly effective, 
but an important result was the ability of cells to survive when treated with D2 alone. A 
lack of cytotoxic effect provides a strong alternative to cytotoxic combination therapies 
currently on the market. Although D2 is not toxic, it does induce synthetic lethality in 
CPT resistant cells when used in combination. Instead of treating patients with several 
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cytotoxic options, compounds that can address the issues of any one treatment type allow 
for better safety for patients and increased sensitivity to cancer therapeutics. The data in 
Figure 14 is convincing when considering the synergistic effects of D2. The increased 
cytotoxicity of the treatment with D2 supports the hypothesis of cell death due to 
blockage of BRCA1 ubiquitination. Results from this assay warrant further work into 
identifying the smallest concentration of both SN38 and D2 while still attaining maximal 
cell death. The clonogenic and MTT assays demonstrated the synergistic effects of D2, 
inducing lethality in resistant cells, and imaging demonstrated stabilization of topoI 
levels.  
Future Experiments 
 Going forward there are confirmatory experiments that would help affirm 
previous findings. To determine if D2 is truly acting to prevent ubiquitination, western 
blots with anti-ubiquitin should be performed. We would expect topoI to be highly 
ubiquitinated in the SN38 treatment group, and a reduction in ubiquitin with the 
combination D2 + SN38 treatment. While imaging topoI stabilization on the microscope, 
we observed that BRCA1 RFP signal was notably higher in D2 + SN38 treatment groups. 
More experiments to understand the localization and movement of BRCA1 in response to 
D2 treatment are needed. In addition, the subG1 assay indicating cell death, was helpful 
in demonstrating the lack of cytotoxicity with D2. The treatment groups including SN38 
and combination SN38 + D2 were abnormal due to overgrowth of cell colonies, however 
the controls were informative. Both the control and D2 control had low percentages of 
subG1 phase cells, indicating low cell death. The similarity between control (3.7% 
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subG1) and D2 control (4.3% subG1) demonstrates the applicability of D2 as a safer 
option for combination therapy. Continuing exploration of the effects of D2 may include 
experiments to determine if the effect of D2 is different on CPT sensitive cell lines, or 
non-cancerous cells. Optimization of D2, and future compounds that address this 
resistance pathway, through further SubG1 assays and MTT assays will help fine tune the 
concentrations needed for effectiveness. 
 Applications of this research is far reaching in concept and use. Further 
exploration of D2 could yield clinically significant results for helping to overcome the 
CPT resistance pathway. More work is needed to gain a greater understanding of the co-
localization of topoI and BRCA1 in the nucleolus, and whether this co-localization can be 
prevented or reduced when BRCA1 binding is prevented. Conceptually speaking, the 
work being done at the Bharti lab is significant for the movement towards personalized 
medicine. Combination therapy is urgently needed to address the resistance and low 
response rates to current cancer therapeutics. Instead of utilizing multiple toxic drugs, 
therapeutics may be geared towards a patient’s specific need and biology, helping 
increase the responsiveness of patients to medications and reduce the toxic effects.  	  
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APPENDIX 
Table 10. Lysate Buffer Ingredients 
Concentration  Substance Amount (µL) 
5 M NaCl 300 
1 M Tris, pH 7.5 500 
100% NP-40 100 
1 M DTT 10 
0.5 M EDTA 20 
 NaF 50 
 NaV 50 
 PMSF 50 
 Pepstatin 50 
 Aprotinin 50 
 MilliQ water 8,820 
 
Table 11. Proportions for 7.5% gel 
 Separating Stacking 
Water 4.9mL 3mL 
Monomer (brown bottle in 
the fridge) 305 acrylamide 
2.5mL 660µL 
Running buffer and SDS 2.6mL 650 and then 700µL 
APS (10% test tube in 
fridge)  
70µL 70µL 
TEMED (Use immediately 
after adding) 
7µL  12µL 
	45 
Table 12. Clonogenic Treatments and Colony Averages 
 
Table 13. Sub G1 Treatments 
Large plate # Wells	 Treatment	 Average	#	Colonies	
 1	 1-3	 Control	(DMSO)	 19.67	4-6	 D2	Control	 18	
 2	 7-9	 0.5	nM	CPT	 19	10-12	 0.5	nM	CPT	+	D2	 9.67	
 3	 13-15	 1.0	nM	CPT	 20	16-18	 1.0	nM	CPT+D2	 10	
 4	 19-21	 2.0	nM	CPT	 17	22-24	 2.0	nM	CPT	+	D2	 8.33	
 5	 25-27	 3.0		nM	CPT	 16.33	28-30	 3.0	nM	CPT	+	D2	 7.67		 6	 31-33	 4.0	nM	CPT	 16		34-36	 4.0	nM	CPT	+	D2	 6.67	
 7	 37-39	 5.0	nM	CPT	 15	40-42	 5.0	nM	CPT	+	D2	 7	
 8	 43-45	 6.0	nM	CPT	 15	46-48	 6.0	nM	CPT	+	D2	 6.33	
 9	 49-51	 10.0	nM	CPT	 11.33	52-54	 10.0	nM	CPT	+	D2	 3.33	
Tube Treatment 
1 Control 
2  MLN control 
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3  D2 Control 
4 50 nM SN38 
5 100 nM SN38 
6 200 nM SN38 
7 300 nM SN38 
8 400 nM SN38 
9 500 nM SN38 
10 50 nM SN38 + D2 
11 100 nM SN38 + D2 
12  200 nM SN38 + D2 
13 300 nM SN38 + D2 
14  400 nM SN38 + D2 
15 500 nM SN38 + D2 
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